<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632579</url>
  </required_header>
  <id_info>
    <org_study_id>14707</org_study_id>
    <secondary_id>I6H-MC-MCBA</secondary_id>
    <nct_id>NCT01632579</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of LY3023703 in Healthy Participants</brief_title>
  <official_title>A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study of LY3023703 in healthy participants. The purposes of this study are
      to look at safety, how well the study drug is tolerated, how much of the study drug gets into
      the blood stream, and how long it takes the body to get rid of it when given to humans.
      Information about any side effects that may occur will also be collected. Participants will
      remain in the study for approximately 3 months. This study is for research purposes only and
      is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AE</measure>
    <time_frame>Baseline up to Day 7 post-dose</time_frame>
    <description>AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible study drug relatedness, is located in the Reported Adverse Events module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY3023703</measure>
    <time_frame>Day 1: pre-dose, 0.25, 0.5, 1, 2, 4, 8 and 12 hours, post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3023703</measure>
    <time_frame>Day 1: pre-dose, 0.25, 0.5, 1, 2, 4, 8 and 12 hours, post-dose</time_frame>
    <description>Area under the concentration time curve from the time of dosing to the time of the last observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percent Change From Baseline of ex Vivo Whole Blood Prostaglandin E (PGE) Synthesis After Lipopolysaccharide (LPS) Stimulation</measure>
    <time_frame>Baseline, 0.5 hours (h), 1 h, 2 h, 8 h, 24 h, and 144 h post-dose</time_frame>
    <description>Percent change from baseline of PGE synthesis=(postdose PGE synthesis-baseline PGE synthesis)/baseline PGE synthesis*100, where the unit of measure for PGE synthesis is nanograms per milliliter (ng/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostaglandin E(2) Metabolite (PGEM)</measure>
    <time_frame>Baseline, 0 to 2 hours (h), 2 to 4 h, 4 to 6 h, 6 to 12 h, and 12 to 24 hours post-dose</time_frame>
    <description>Urinary excretion of PGEM, after correcting for urinary creatinine. PGEM was corrected for urinary creatinine by dividing the picograms per milliliter (pg/mL) of metabolite excreted in urine by the concentration of creatinine [milligrams per milliliter (mg/mL)] in urine. Percent change from baseline of urinary excretion of PGEM=(mg creatinine per pg of metabolite excreted in urine postdose-mg of creatinine per pg of metabolite excreted at baseline)/mg of creatinine per pg of metabolite excreted at baseline*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostacyclin Metabolite (PGIM)</measure>
    <time_frame>Baseline, 0 to 2 hours (h), 2 to 4 h, 4 to 6 h, and 6 to 12 h post-dose</time_frame>
    <description>Urinary excretion of PGIM, after correcting for urinary creatinine. PGIM was corrected for urinary creatinine by dividing the picograms per milliliter (pg/mL) of metabolite excreted in urine by the concentration of creatinine [milligrams per milliliter (mg/mL)] in urine. Percent change from baseline of urinary excretion of PGIM=(mg creatinine per pg of metabolite excreted in urine postdose-mg of creatinine per pg of metabolite excreted at baseline)/mg of creatinine per pg of metabolite excreted at baseline*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Thromboxane A Metabolite (TXAM)</measure>
    <time_frame>Baseline, 0 to 2 hours (h), 2 to 4 h, 4 to 6 h, and 6 to 12 h post-dose</time_frame>
    <description>Urinary excretion of TXAM, after correcting for urinary creatinine. TXAM was corrected for urinary creatinine by dividing the picograms per milliliter (pg/mL) of metabolite excreted in urine by the concentration of creatinine [milligrams per milliliter (mg/mL)] in urine. Percent change from baseline of urinary excretion of TXAM=(mg creatinine per pg of metabolite excreted in urine postdose-mg of creatinine per pg of metabolite excreted at baseline)/mg of creatinine per pg of metabolite excreted at baseline*100.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered orally on up to one occasion separated by at least a 3 week wash out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3023703</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 6 single escalating doses of LY3023703 [0.1 milligram (mg) up to 60 mg] administered orally on up to two occasions per participant separated by at least a 3 week wash out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Positive control. Single 400 mg dose of celecoxib administered orally, open label, on one occasion separated by at least a 3 week washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3023703</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3023703</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>400 mg Celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy individuals based on the history and physical examinations as
             determined by the investigator

          -  Body mass index between 18.5 and 32.0 kilograms per square meter (kg/m^2), inclusive

        Exclusion Criteria:

          -  Have known allergies to LY3023703 or any components of the formulation, celecoxib, or
             sulfonamides. Participants with known aspirin allergy, allergic reaction to
             nonsteroidal anti-inflammatory drugs (NSAIDs), or allergies or intolerance to other
             selective microsomal prostaglandin E synthase (mPGES-1) inhibitors should also be
             excluded

          -  Have the presence of active peptic ulcer disease, gastrointestinal (GI) bleeding,
             chronic gastritis, inflammatory bowel disease, or chronic diarrhea, or positive
             Helicobacter pylori serology

          -  Use NSAIDs, celecoxib, aspirin, or acetaminophen (at doses greater than 1 gram per
             day) within 14 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 25, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2012</study_first_posted>
  <results_first_submitted>September 27, 2017</results_first_submitted>
  <results_first_submitted_qc>July 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2018</results_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study had 3 periods. Period 1: 0.1 milligram (mg), 0.5 mg, 2.5 mg LY3023703 or placebo. Period 2: 10 mg, 30 mg, 60 mg LY3023703 or placebo. Period 3: 400 mg celecoxib. There was at least a 3-week washout between periods and at least 7 days between dosing of each cohort in Periods 1 and 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 Sequence 1</title>
          <description>Participants received LY3023703, placebo and celecoxib capsules orally as per the below dosing sequence in each period.
Period 1: 0.1 mg LY3023703 in week 1, Period 2: Placebo in week 4 and Period 3: 400mg celecoxib in week 8.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 Sequence 2</title>
          <description>Participants received LY3023703 and celecoxib capsules orally as per the below dosing sequence in each period.
Period 1: 0.1 mg LY3023703 in week 1, Period 2: 10 mg LY3023703 in week 4 and Period 3: 400mg celecoxib in week 7.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1 Sequence 3</title>
          <description>Participants received placebo, LY3023703 and celecoxib capsules orally as per the below dosing sequence in each period.
Period 1: Placebo in week 1, Period 2: 10 mg LY3023703 in week 4 and Period 3: 400mg celecoxib in week 7.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 Sequence 1</title>
          <description>Participants received LY3023703, placebo and celecoxib capsules orally as per the below dosing sequence in each period.
Period 1: 0.5 mg LY3023703 in week 2, Period 2: Placebo in week 5 and Period 3: 400mg celecoxib in week 8.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 2 Sequence 2</title>
          <description>Participants received LY3023703 and celecoxib capsules orally as per the below dosing sequence in each period.
Period 1: 0.5 mg LY3023703 in week 2, Period 2: 30 mg LY3023703 in week 5 and Period 3: 400mg celecoxib in week 8.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 2 Sequence 3</title>
          <description>Participants received placebo, LY3023703 and celecoxib capsules orally as per the below dosing sequence in each period.
Period 1: Placebo in week 2, Period 2: 30 mg LY3023703 in week 5 and Period 3: 400mg celecoxib in week 8.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 3 Sequence 1</title>
          <description>Participants received LY3023703, placebo and celecoxib capsules orally as per the below dosing sequence in each period.
Period 1: 2.5 mg LY3023703 in week 3, Period 2: Placebo in week 6 and Period 3: 400mg celecoxib in week 9.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 3 Sequence 2</title>
          <description>Participants received LY3023703 and celecoxib capsules orally as per the below dosing sequence in each period.
Period 1: 2.5 mg LY3023703 in week 3, Period 2: 60 mg LY3023703 in week 6 and Period 3: 400mg celecoxib in week 9.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 3 Sequence 3</title>
          <description>Participants received placebo, LY3023703 and celecoxib capsules orally as per the below dosing sequence in each period.
Period 1: Placebo in week 3, Period 2: 60 mg LY3023703 in week 6 and Period 3: 400mg celecoxib in week 9.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (First Intervention)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (Second Intervention)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 (Third Intervention)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Depending on the cohort and period, participants received either an LY3023703 capsule (0.1-mg, 0.5-mg, 2.5-mg, 10-mg, 30-mg, or 60-mg strength) or placebo administered orally once in Periods 1 and 2. In Period 3, participants were administered 400 mg celecoxib, orally. Each dose of study drug was followed by a washout period of at least 3 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AE</title>
        <description>AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible study drug relatedness, is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline up to Day 7 post-dose</time_frame>
        <population>Safety population: participants who received at least 1 dose of study drug or placebo, whether or not he/she completed all the protocol requirements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally in Periods 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>0.1 mg LY3023703</title>
            <description>0.1-milligram (mg) LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>0.5 mg LY3023703</title>
            <description>0.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>2.5 mg LY3023703</title>
            <description>2.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3023703</title>
            <description>10-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O6">
            <title>30 mg LY3023703</title>
            <description>30-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>60 mg LY3023703</title>
            <description>60-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O8">
            <title>Celecoxib</title>
            <description>400-mg celecoxib dose (two 200-mg celecoxib capsules) administered orally, once in Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AE</title>
          <description>AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible study drug relatedness, is located in the Reported Adverse Events module.</description>
          <population>Safety population: participants who received at least 1 dose of study drug or placebo, whether or not he/she completed all the protocol requirements.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-Related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY3023703</title>
        <time_frame>Day 1: pre-dose, 0.25, 0.5, 1, 2, 4, 8 and 12 hours, post-dose</time_frame>
        <population>Pharmacokinetic (PK) population: participants who received at least 1 dose of study drug and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg LY3023703</title>
            <description>0.1-milligram (mg) LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>0.5 mg LY3023703</title>
            <description>0.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>2.5 mg LY3023703</title>
            <description>2.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>10 mg LY3023703</title>
            <description>10-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O5">
            <title>30 mg LY3023703</title>
            <description>30-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O6">
            <title>60 mg LY3023703</title>
            <description>60-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY3023703</title>
          <population>Pharmacokinetic (PK) population: participants who received at least 1 dose of study drug and had evaluable Cmax data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="25.4"/>
                    <measurement group_id="O2" value="5.66" spread="27.7"/>
                    <measurement group_id="O3" value="23.5" spread="23.7"/>
                    <measurement group_id="O4" value="140" spread="22.0"/>
                    <measurement group_id="O5" value="547" spread="36.0"/>
                    <measurement group_id="O6" value="756" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3023703</title>
        <description>Area under the concentration time curve from the time of dosing to the time of the last observation.</description>
        <time_frame>Day 1: pre-dose, 0.25, 0.5, 1, 2, 4, 8 and 12 hours, post-dose</time_frame>
        <population>Pharmacokinetic (PK) population: All participants who received at least 1 dose of study drug and had evaluable AUC data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg LY3023703</title>
            <description>0.1-milligram (mg) LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>0.5 mg LY3023703</title>
            <description>0.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>2.5 mg LY3023703</title>
            <description>2.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>10 mg LY3023703</title>
            <description>10-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O5">
            <title>30 mg LY3023703</title>
            <description>30-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O6">
            <title>60 mg LY3023703</title>
            <description>60-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3023703</title>
          <description>Area under the concentration time curve from the time of dosing to the time of the last observation.</description>
          <population>Pharmacokinetic (PK) population: All participants who received at least 1 dose of study drug and had evaluable AUC data.</population>
          <units>hour*nanograms per milliliter (hr*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="52.0"/>
                    <measurement group_id="O2" value="54.7" spread="72.4"/>
                    <measurement group_id="O3" value="245" spread="58.5"/>
                    <measurement group_id="O4" value="1680" spread="36.8"/>
                    <measurement group_id="O5" value="9940" spread="45.6"/>
                    <measurement group_id="O6" value="13800" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Percent Change From Baseline of ex Vivo Whole Blood Prostaglandin E (PGE) Synthesis After Lipopolysaccharide (LPS) Stimulation</title>
        <description>Percent change from baseline of PGE synthesis=(postdose PGE synthesis-baseline PGE synthesis)/baseline PGE synthesis*100, where the unit of measure for PGE synthesis is nanograms per milliliter (ng/ml).</description>
        <time_frame>Baseline, 0.5 hours (h), 1 h, 2 h, 8 h, 24 h, and 144 h post-dose</time_frame>
        <population>All participants who received at least 1 dose of study drug or placebo and had evaluable PGE data at the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally in Periods 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>0.1 mg LY3023703</title>
            <description>0.1-milligram (mg) LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>0.5 mg LY3023703</title>
            <description>0.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>2.5 mg LY3023703</title>
            <description>2.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3023703</title>
            <description>10-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O6">
            <title>30 mg LY3023703</title>
            <description>30-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>60 mg LY3023703</title>
            <description>60-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O8">
            <title>Celecoxib</title>
            <description>400-mg celecoxib dose (two 200-mg celecoxib capsules) administered orally, once in Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Percent Change From Baseline of ex Vivo Whole Blood Prostaglandin E (PGE) Synthesis After Lipopolysaccharide (LPS) Stimulation</title>
          <description>Percent change from baseline of PGE synthesis=(postdose PGE synthesis-baseline PGE synthesis)/baseline PGE synthesis*100, where the unit of measure for PGE synthesis is nanograms per milliliter (ng/ml).</description>
          <population>All participants who received at least 1 dose of study drug or placebo and had evaluable PGE data at the specific time points.</population>
          <units>percent change in PGE</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at 0.5 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" lower_limit="-36.7" upper_limit="71.2"/>
                    <measurement group_id="O2" value="102.6" lower_limit="102.6" upper_limit="102.6"/>
                    <measurement group_id="O3" value="-11.6" lower_limit="-34.0" upper_limit="3.3"/>
                    <measurement group_id="O4" value="29.3" lower_limit="-9.0" upper_limit="91.4"/>
                    <measurement group_id="O5" value="-12.1" lower_limit="-37.9" upper_limit="22.2"/>
                    <measurement group_id="O6" value="-43.5" lower_limit="-65.6" upper_limit="-14.3"/>
                    <measurement group_id="O7" value="-27.1" lower_limit="-46.8" upper_limit="-4.5"/>
                    <measurement group_id="O8" value="-7.1" lower_limit="-23.6" upper_limit="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 1 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" lower_limit="-43.9" upper_limit="71.5"/>
                    <measurement group_id="O2" value="106.4" lower_limit="106.4" upper_limit="106.4"/>
                    <measurement group_id="O3" value="-6.2" lower_limit="-46.4" upper_limit="27.3"/>
                    <measurement group_id="O4" value="-18.9" lower_limit="-46.8" upper_limit="21.8"/>
                    <measurement group_id="O5" value="-67.6" lower_limit="-76.9" upper_limit="-23.8"/>
                    <measurement group_id="O6" value="-84.1" lower_limit="-99.8" upper_limit="-77.7"/>
                    <measurement group_id="O7" value="-82.4" lower_limit="-95.1" upper_limit="-62.1"/>
                    <measurement group_id="O8" value="-14.0" lower_limit="-47.1" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="-27.1" upper_limit="103.2"/>
                    <measurement group_id="O2" value="87.9" lower_limit="87.9" upper_limit="87.9"/>
                    <measurement group_id="O3" value="52.1" lower_limit="4.9" upper_limit="61.5"/>
                    <measurement group_id="O4" value="-59.6" lower_limit="-64.6" upper_limit="-21.9"/>
                    <measurement group_id="O5" value="-82.7" lower_limit="-92.3" upper_limit="-74.3"/>
                    <measurement group_id="O6" value="-102.0" lower_limit="-130.1" upper_limit="-97.0"/>
                    <measurement group_id="O7" value="-89.1" lower_limit="-93.9" upper_limit="-76.8"/>
                    <measurement group_id="O8" value="-42.5" lower_limit="-60.0" upper_limit="-25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 8 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="-28.4" upper_limit="75.8"/>
                    <measurement group_id="O2" value="44.2" lower_limit="44.2" upper_limit="44.2"/>
                    <measurement group_id="O3" value="90.5" lower_limit="76.6" upper_limit="113.7"/>
                    <measurement group_id="O4" value="3.3" lower_limit="-16.1" upper_limit="40.1"/>
                    <measurement group_id="O5" value="-56.0" lower_limit="-81.9" upper_limit="-52.0"/>
                    <measurement group_id="O6" value="-96.5" lower_limit="-111.8" upper_limit="-94.4"/>
                    <measurement group_id="O7" value="-96.1" lower_limit="-100.6" upper_limit="-87.4"/>
                    <measurement group_id="O8" value="-26.7" lower_limit="-42.7" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.0" lower_limit="-47.1" upper_limit="8.8"/>
                    <measurement group_id="O3" value="44.1" lower_limit="27.5" upper_limit="65.0"/>
                    <measurement group_id="O4" value="-7.6" lower_limit="-14.7" upper_limit="84.1"/>
                    <measurement group_id="O5" value="16.1" lower_limit="-29.9" upper_limit="94.4"/>
                    <measurement group_id="O6" value="-84.2" lower_limit="-87.1" upper_limit="-78.1"/>
                    <measurement group_id="O7" value="-80.7" lower_limit="-85.6" upper_limit="-64.2"/>
                    <measurement group_id="O8" value="-21.8" lower_limit="-49.9" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 144 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.8" lower_limit="-68.0" upper_limit="-19.4"/>
                    <measurement group_id="O2" value="-31.1" lower_limit="-31.1" upper_limit="-31.1"/>
                    <measurement group_id="O3" value="20.5" lower_limit="-32.0" upper_limit="66.6"/>
                    <measurement group_id="O4" value="28.9" lower_limit="-25.3" upper_limit="103.9"/>
                    <measurement group_id="O5" value="111.6" lower_limit="66.9" upper_limit="117.9"/>
                    <measurement group_id="O6" value="-61.3" lower_limit="-115.7" upper_limit="68.6"/>
                    <measurement group_id="O7" value="4.3" lower_limit="-21.2" upper_limit="36.0"/>
                    <measurement group_id="O8" value="11.6" lower_limit="-28.8" upper_limit="190.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostaglandin E(2) Metabolite (PGEM)</title>
        <description>Urinary excretion of PGEM, after correcting for urinary creatinine. PGEM was corrected for urinary creatinine by dividing the picograms per milliliter (pg/mL) of metabolite excreted in urine by the concentration of creatinine [milligrams per milliliter (mg/mL)] in urine. Percent change from baseline of urinary excretion of PGEM=(mg creatinine per pg of metabolite excreted in urine postdose-mg of creatinine per pg of metabolite excreted at baseline)/mg of creatinine per pg of metabolite excreted at baseline*100.</description>
        <time_frame>Baseline, 0 to 2 hours (h), 2 to 4 h, 4 to 6 h, 6 to 12 h, and 12 to 24 hours post-dose</time_frame>
        <population>All participants who received at least 1 dose of study drug or placebo and had evaluable PGEM data at specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally in Periods 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>0.1 mg LY3023703</title>
            <description>0.1-milligram (mg) LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>0.5 mg LY3023703</title>
            <description>0.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>2.5 mg LY3023703</title>
            <description>2.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3023703</title>
            <description>10-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O6">
            <title>30 mg LY3023703</title>
            <description>30-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>60 mg LY3023703</title>
            <description>60-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O8">
            <title>Celecoxib</title>
            <description>400-mg celecoxib dose (two 200-mg celecoxib capsules) administered orally, once in Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostaglandin E(2) Metabolite (PGEM)</title>
          <description>Urinary excretion of PGEM, after correcting for urinary creatinine. PGEM was corrected for urinary creatinine by dividing the picograms per milliliter (pg/mL) of metabolite excreted in urine by the concentration of creatinine [milligrams per milliliter (mg/mL)] in urine. Percent change from baseline of urinary excretion of PGEM=(mg creatinine per pg of metabolite excreted in urine postdose-mg of creatinine per pg of metabolite excreted at baseline)/mg of creatinine per pg of metabolite excreted at baseline*100.</description>
          <population>All participants who received at least 1 dose of study drug or placebo and had evaluable PGEM data at specific time points.</population>
          <units>percent change in PGEM</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at 0 to 2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="-26.3" upper_limit="30.2"/>
                    <measurement group_id="O2" value="7.4" lower_limit="-35.3" upper_limit="14.7"/>
                    <measurement group_id="O3" value="-4.0" lower_limit="-19.7" upper_limit="19.8"/>
                    <measurement group_id="O4" value="1.5" lower_limit="-15.8" upper_limit="17.6"/>
                    <measurement group_id="O5" value="-5.3" lower_limit="-21.0" upper_limit="47.5"/>
                    <measurement group_id="O6" value="17.7" lower_limit="-24.8" upper_limit="35.9"/>
                    <measurement group_id="O7" value="-6.6" lower_limit="-25.8" upper_limit="52.0"/>
                    <measurement group_id="O8" value="-7.5" lower_limit="-28.3" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 2 to 4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-30.1" upper_limit="52.0"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-19.4" upper_limit="20.4"/>
                    <measurement group_id="O3" value="7.9" lower_limit="-15.8" upper_limit="30.3"/>
                    <measurement group_id="O4" value="-0.8" lower_limit="-25.8" upper_limit="5.3"/>
                    <measurement group_id="O5" value="-21.0" lower_limit="-44.8" upper_limit="7.8"/>
                    <measurement group_id="O6" value="-46.6" lower_limit="-52.3" upper_limit="-24.0"/>
                    <measurement group_id="O7" value="-25.1" lower_limit="-47.7" upper_limit="25.2"/>
                    <measurement group_id="O8" value="-41.5" lower_limit="-51.3" upper_limit="-21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 4 to 6 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.0" lower_limit="-33.7" upper_limit="20.6"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-37.8" upper_limit="2.9"/>
                    <measurement group_id="O3" value="-25.0" lower_limit="-42.4" upper_limit="-8.9"/>
                    <measurement group_id="O4" value="-19.0" lower_limit="-39.7" upper_limit="-6.7"/>
                    <measurement group_id="O5" value="-29.1" lower_limit="-51.6" upper_limit="-9.0"/>
                    <measurement group_id="O6" value="-53.0" lower_limit="-62.5" upper_limit="-35.7"/>
                    <measurement group_id="O7" value="-42.4" lower_limit="-57.3" upper_limit="26.9"/>
                    <measurement group_id="O8" value="-55.0" lower_limit="-70.3" upper_limit="-42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 6 to 12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" lower_limit="-45.5" upper_limit="11.9"/>
                    <measurement group_id="O2" value="-18.5" lower_limit="-36.7" upper_limit="7.3"/>
                    <measurement group_id="O3" value="2.3" lower_limit="-31.1" upper_limit="10.8"/>
                    <measurement group_id="O4" value="-20.4" lower_limit="-27.4" upper_limit="-7.2"/>
                    <measurement group_id="O5" value="-39.5" lower_limit="-57.9" upper_limit="-23.4"/>
                    <measurement group_id="O6" value="-37.5" lower_limit="-62.3" upper_limit="-19.2"/>
                    <measurement group_id="O7" value="-48.0" lower_limit="-58.0" upper_limit="-9.5"/>
                    <measurement group_id="O8" value="-49.7" lower_limit="-68.9" upper_limit="-27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 12 to 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7" lower_limit="-39.3" upper_limit="8.6"/>
                    <measurement group_id="O2" value="-38.8" lower_limit="-42.1" upper_limit="-22.9"/>
                    <measurement group_id="O3" value="-18.0" lower_limit="-35.8" upper_limit="9.2"/>
                    <measurement group_id="O4" value="-19.1" lower_limit="-39.9" upper_limit="-3.5"/>
                    <measurement group_id="O5" value="-28.8" lower_limit="-42.6" upper_limit="43.3"/>
                    <measurement group_id="O6" value="-31.2" lower_limit="-47.7" upper_limit="-8.6"/>
                    <measurement group_id="O7" value="-53.0" lower_limit="-74.9" upper_limit="-19.9"/>
                    <measurement group_id="O8" value="-46.2" lower_limit="-59.2" upper_limit="-11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostacyclin Metabolite (PGIM)</title>
        <description>Urinary excretion of PGIM, after correcting for urinary creatinine. PGIM was corrected for urinary creatinine by dividing the picograms per milliliter (pg/mL) of metabolite excreted in urine by the concentration of creatinine [milligrams per milliliter (mg/mL)] in urine. Percent change from baseline of urinary excretion of PGIM=(mg creatinine per pg of metabolite excreted in urine postdose-mg of creatinine per pg of metabolite excreted at baseline)/mg of creatinine per pg of metabolite excreted at baseline*100.</description>
        <time_frame>Baseline, 0 to 2 hours (h), 2 to 4 h, 4 to 6 h, and 6 to 12 h post-dose</time_frame>
        <population>All participants who received at least 1 dose of study drug or placebo and had evaluable PGIM data at specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally in Periods 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>0.1 mg LY3023703</title>
            <description>0.1-milligram (mg) LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>0.5 mg LY3023703</title>
            <description>0.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>2.5 mg LY3023703</title>
            <description>2.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3023703</title>
            <description>10-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O6">
            <title>30 mg LY3023703</title>
            <description>30-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>60 mg LY3023703</title>
            <description>60-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O8">
            <title>Celecoxib</title>
            <description>400-mg celecoxib dose (two 200-mg celecoxib capsules) administered orally, once in Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostacyclin Metabolite (PGIM)</title>
          <description>Urinary excretion of PGIM, after correcting for urinary creatinine. PGIM was corrected for urinary creatinine by dividing the picograms per milliliter (pg/mL) of metabolite excreted in urine by the concentration of creatinine [milligrams per milliliter (mg/mL)] in urine. Percent change from baseline of urinary excretion of PGIM=(mg creatinine per pg of metabolite excreted in urine postdose-mg of creatinine per pg of metabolite excreted at baseline)/mg of creatinine per pg of metabolite excreted at baseline*100.</description>
          <population>All participants who received at least 1 dose of study drug or placebo and had evaluable PGIM data at specific time points.</population>
          <units>percent change in PGIM</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at 0 to 2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" lower_limit="-21.6" upper_limit="19.6"/>
                    <measurement group_id="O2" value="-34.6" lower_limit="-50.5" upper_limit="-13.2"/>
                    <measurement group_id="O3" value="15.5" lower_limit="-0.9" upper_limit="46.2"/>
                    <measurement group_id="O4" value="22.4" lower_limit="3.5" upper_limit="41.9"/>
                    <measurement group_id="O5" value="-1.2" lower_limit="-27.3" upper_limit="23.7"/>
                    <measurement group_id="O6" value="33.1" lower_limit="-11.9" upper_limit="91.1"/>
                    <measurement group_id="O7" value="27.7" lower_limit="-15.6" upper_limit="102.0"/>
                    <measurement group_id="O8" value="-32.0" lower_limit="-39.2" upper_limit="-16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 2 to 4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" lower_limit="-34.5" upper_limit="-2.2"/>
                    <measurement group_id="O2" value="-19.6" lower_limit="-34.3" upper_limit="-13.7"/>
                    <measurement group_id="O3" value="18.6" lower_limit="-18.5" upper_limit="49.2"/>
                    <measurement group_id="O4" value="9.8" lower_limit="-3.3" upper_limit="64.5"/>
                    <measurement group_id="O5" value="29.3" lower_limit="10.0" upper_limit="58.8"/>
                    <measurement group_id="O6" value="51.5" lower_limit="16.3" upper_limit="65.6"/>
                    <measurement group_id="O7" value="74.5" lower_limit="-29.6" upper_limit="128.2"/>
                    <measurement group_id="O8" value="-66.0" lower_limit="-75.9" upper_limit="-46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 4 to 6 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-29.6" upper_limit="29.7"/>
                    <measurement group_id="O2" value="-19.1" lower_limit="-58.5" upper_limit="-5.8"/>
                    <measurement group_id="O3" value="-3.5" lower_limit="-13.7" upper_limit="11.9"/>
                    <measurement group_id="O4" value="3.7" lower_limit="-17.3" upper_limit="23.2"/>
                    <measurement group_id="O5" value="-0.9" lower_limit="-27.4" upper_limit="36.4"/>
                    <measurement group_id="O6" value="19.5" lower_limit="-2.6" upper_limit="67.4"/>
                    <measurement group_id="O7" value="63.3" lower_limit="-18.3" upper_limit="138.3"/>
                    <measurement group_id="O8" value="-60.0" lower_limit="-68.2" upper_limit="-53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 6 to 12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" lower_limit="-11.0" upper_limit="15.9"/>
                    <measurement group_id="O2" value="-29.8" lower_limit="-35.3" upper_limit="39.4"/>
                    <measurement group_id="O3" value="13.6" lower_limit="-0.1" upper_limit="19.6"/>
                    <measurement group_id="O4" value="0.6" lower_limit="-7.6" upper_limit="37.6"/>
                    <measurement group_id="O5" value="98.4" lower_limit="4.9" upper_limit="112.3"/>
                    <measurement group_id="O6" value="44.1" lower_limit="14.0" upper_limit="98.3"/>
                    <measurement group_id="O7" value="49.9" lower_limit="-10.9" upper_limit="138.7"/>
                    <measurement group_id="O8" value="-45.2" lower_limit="-57.7" upper_limit="-23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Thromboxane A Metabolite (TXAM)</title>
        <description>Urinary excretion of TXAM, after correcting for urinary creatinine. TXAM was corrected for urinary creatinine by dividing the picograms per milliliter (pg/mL) of metabolite excreted in urine by the concentration of creatinine [milligrams per milliliter (mg/mL)] in urine. Percent change from baseline of urinary excretion of TXAM=(mg creatinine per pg of metabolite excreted in urine postdose-mg of creatinine per pg of metabolite excreted at baseline)/mg of creatinine per pg of metabolite excreted at baseline*100.</description>
        <time_frame>Baseline, 0 to 2 hours (h), 2 to 4 h, 4 to 6 h, and 6 to 12 h post-dose</time_frame>
        <population>All participants who received at least 1 dose of study drug or placebo and had evaluable TXAM data at specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally in Periods 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>0.1 mg LY3023703</title>
            <description>0.1-milligram (mg) LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>0.5 mg LY3023703</title>
            <description>0.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>2.5 mg LY3023703</title>
            <description>2.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3023703</title>
            <description>10-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O6">
            <title>30 mg LY3023703</title>
            <description>30-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>60 mg LY3023703</title>
            <description>60-mg LY3023703 capsule administered orally, once in Period 2.</description>
          </group>
          <group group_id="O8">
            <title>Celecoxib</title>
            <description>400-mg celecoxib dose (two 200-mg celecoxib capsules) administered orally, once in Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Thromboxane A Metabolite (TXAM)</title>
          <description>Urinary excretion of TXAM, after correcting for urinary creatinine. TXAM was corrected for urinary creatinine by dividing the picograms per milliliter (pg/mL) of metabolite excreted in urine by the concentration of creatinine [milligrams per milliliter (mg/mL)] in urine. Percent change from baseline of urinary excretion of TXAM=(mg creatinine per pg of metabolite excreted in urine postdose-mg of creatinine per pg of metabolite excreted at baseline)/mg of creatinine per pg of metabolite excreted at baseline*100.</description>
          <population>All participants who received at least 1 dose of study drug or placebo and had evaluable TXAM data at specific time points.</population>
          <units>percent change in TXAM</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at 0 to 2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" lower_limit="-24.2" upper_limit="3.4"/>
                    <measurement group_id="O2" value="-19.9" lower_limit="-23.6" upper_limit="-8.4"/>
                    <measurement group_id="O3" value="6.5" lower_limit="-14.1" upper_limit="32.4"/>
                    <measurement group_id="O4" value="-17.9" lower_limit="-29.7" upper_limit="-5.8"/>
                    <measurement group_id="O5" value="8.7" lower_limit="-17.2" upper_limit="17.0"/>
                    <measurement group_id="O6" value="2.7" lower_limit="-13.4" upper_limit="30.4"/>
                    <measurement group_id="O7" value="-10.2" lower_limit="-19.8" upper_limit="-0.1"/>
                    <measurement group_id="O8" value="-5.0" lower_limit="-22.5" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 2 to 4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" lower_limit="-23.4" upper_limit="3.4"/>
                    <measurement group_id="O2" value="-11.5" lower_limit="-25.5" upper_limit="-3.7"/>
                    <measurement group_id="O3" value="11.1" lower_limit="-4.8" upper_limit="23.0"/>
                    <measurement group_id="O4" value="-7.9" lower_limit="-23.8" upper_limit="2.1"/>
                    <measurement group_id="O5" value="21.4" lower_limit="13.6" upper_limit="31.3"/>
                    <measurement group_id="O6" value="26.3" lower_limit="4.1" upper_limit="43.1"/>
                    <measurement group_id="O7" value="13.0" lower_limit="-2.3" upper_limit="37.3"/>
                    <measurement group_id="O8" value="-17.7" lower_limit="-30.8" upper_limit="-5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 4 to 6 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0" lower_limit="-21.4" upper_limit="2.1"/>
                    <measurement group_id="O2" value="-19.8" lower_limit="-24.3" upper_limit="-5.7"/>
                    <measurement group_id="O3" value="2.6" lower_limit="-4.7" upper_limit="12.3"/>
                    <measurement group_id="O4" value="-18.8" lower_limit="-20.9" upper_limit="-13.6"/>
                    <measurement group_id="O5" value="16.4" lower_limit="-1.0" upper_limit="32.5"/>
                    <measurement group_id="O6" value="-13.1" lower_limit="-25.2" upper_limit="7.4"/>
                    <measurement group_id="O7" value="18.5" lower_limit="-3.7" upper_limit="22.0"/>
                    <measurement group_id="O8" value="-25.7" lower_limit="-37.8" upper_limit="-18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at 6 to 12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" lower_limit="-21.5" upper_limit="5.5"/>
                    <measurement group_id="O2" value="-13.8" lower_limit="-20.1" upper_limit="-8.6"/>
                    <measurement group_id="O3" value="7.7" lower_limit="-2.2" upper_limit="11.7"/>
                    <measurement group_id="O4" value="-19.2" lower_limit="-23.1" upper_limit="-12.3"/>
                    <measurement group_id="O5" value="18.0" lower_limit="8.7" upper_limit="28.8"/>
                    <measurement group_id="O6" value="9.8" lower_limit="-12.1" upper_limit="37.7"/>
                    <measurement group_id="O7" value="19.1" lower_limit="14.6" upper_limit="31.8"/>
                    <measurement group_id="O8" value="-16.2" lower_limit="-26.0" upper_limit="-4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matched placebo capsules administered orally in Periods 1 or 2.</description>
        </group>
        <group group_id="E2">
          <title>LY3023703 0.1 mg</title>
          <description>0.1-milligram (mg) LY3023703 capsule administered orally, once in Period 1.</description>
        </group>
        <group group_id="E3">
          <title>LY3023703 0.5 mg</title>
          <description>0.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
        </group>
        <group group_id="E4">
          <title>LY3023703 2.5 mg</title>
          <description>2.5-mg LY3023703 capsule administered orally, once in Period 1.</description>
        </group>
        <group group_id="E5">
          <title>LY3023703 10 mg</title>
          <description>10-mg LY3023703 capsule administered orally, once in Period 2.</description>
        </group>
        <group group_id="E6">
          <title>LY3023703 30 mg</title>
          <description>30-mg LY3023703 capsule administered orally, once in Period 2.</description>
        </group>
        <group group_id="E7">
          <title>LY3023703 60 mg</title>
          <description>60-mg LY3023703 capsule administered orally, once in Period 2.</description>
        </group>
        <group group_id="E8">
          <title>Celecoxib</title>
          <description>400-mg celecoxib capsule, administered orally, once in Period 3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

